{
    "clinical_study": {
        "@rank": "90931", 
        "brief_summary": {
            "textblock": "To assess the tolerance and toxicity profile of deoxy-3'-fluorothymidine (FLT) after\n      multiple oral dosing for 16 weeks. To characterize the steady-state pharmacokinetics of FLT\n      after multiple oral doses. To assess the effect of FLT on immunologic and virologic markers\n      of HIV infection (CD4+ lymphocyte count, p24 antigen, viremia) in patients with AIDS or AIDS\n      related complex (ARC) after multiple oral dosing for 16 weeks."
        }, 
        "brief_title": "A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "AIDS-Related Complex"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis.\n\n          -  Up to 14 days of systemic therapy for minor opportunistic infections such as\n             candidiasis, mucocutaneous Herpes simplex or cutaneous Herpes zoster infections.\n\n        Patients must have the following:\n\n          -  AIDS or AIDS related complex (ARC) as defined by the CDC.\n\n          -  Positive antibody to HIV as determined by a commercially licensed ELISA test kit,\n             confirmed by Western blot analysis.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Symptomatic visceral Kaposi's sarcoma or progression of Kaposi's sarcoma within the\n             month prior to study entry (progression is defined as more than a 25 percent increase\n             in the product of bidirectional measurement of indicator lesions and/or more than a\n             25 percent increase in the number of new lesions).\n\n          -  Concurrent neoplasms other than Kaposi's sarcoma or basal cell carcinoma of the skin.\n             Patients who have had a malignancy in the past that has been in complete remission\n             for 1 year without therapy may be enrolled.\n\n          -  Signs or symptoms of neuropathy and a Vibratron 2 score = or > 4 for either great\n             toe.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Acute therapy for AIDS-related infection.\n\n          -  Systemic maintenance therapy for AIDS-defining opportunistic infection.\n\n          -  Recombinant erythropoietin.\n\n          -  Long term therapy with either aspirin or probenecid.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Blood transfusion more than once per month.\n\n        Patients with the following are excluded:\n\n          -  Symptomatic visceral Kaposi's sarcoma or progression of Kaposi's sarcoma within the\n             month prior to study entry.\n\n          -  Unwilling to sign an informed consent or patients unwilling to be followed at the\n             medical center where they were enrolled for the duration of the study and follow-up\n             as required.\n\n          -  History of intolerance to zidovudine (AZT) at any dose as demonstrated by an AZT\n             related decrease in hemoglobin levels of at least 2 g/dl or AZT related depression of\n             neutrophils of at least 200 cells/mm3 to < 750 cells/mm3 which required\n             discontinuation of AZT therapy.\n\n          -  Diseases or conditions listed in Exclusion Co-Existing Conditions.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Antiretroviral agents within 14 days of study entry.\n\n          -  Immunomodulating agents or corticosteroids within 30 days prior to study entry.\n\n          -  Treatment for acute Pneumocystis carinii pneumonia within 2 weeks prior to study\n             entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Blood transfusions within 7 days prior to study entry.\n\n          -  Radiation therapy for Kaposi's sarcoma within 30 days prior to study entry.\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002254", 
            "org_study_id": "054B", 
            "secondary_id": "81-2"
        }, 
        "intervention": {
            "intervention_name": "Alovudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Alovudine", 
                "Dideoxynucleosides"
            ]
        }, 
        "keyword": "Acquired Immunodeficiency Syndrome", 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Mem Sloan - Kettering Cancer Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "275997215"
                    }, 
                    "name": "Univ of North Carolina School of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Barditch-Crovo PA, Kornhauser DM, Petty BG, Nerhood LJ, Lietman PS, Faulkner R, Ganes D, Kuye O, Flexner C. Phase I pharmacokinetic evaluation of 3'deoxy-3'-fluorothymidine (FLT), a new potent anti-HIV nucleoside. Int Conf AIDS. 1991 Jun 16-21;7(2):210 (abstract no WB2114)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002254"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lederle Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1991"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "Mem Sloan - Kettering Cancer Ctr": "40.714 -74.006", 
        "Univ of North Carolina School of Medicine": "35.913 -79.056"
    }
}